Dipexium Pharmaceuticals, a late stage biotech developing novel antibiotic treatments for diabetic foot ulcers, filed on Thursday with the SEC to raise up to $35 million in an initial public offering. The New York, NY-based company, which was founded in 2010, plans to list on the NASDAQ under the symbol DPRX. Dipexium Pharmaceuticals initially filed confidentially on December 23, 2013. Oppenheimer & Co. is the sole bookrunner on the deal. No pricing terms were disclosed.
